Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone-Reference-Cited by-同舟云学术

Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone

Published:2011-01 Issue:1 Volume:35 Page:80-86
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Nicolini Franck E.,Hayette Sandrine,Legros Laurence,Rousselot Philippe,Maloisel Frédéric,Tulliez Michel,Guerci Agnès,Charbonnier Aude,Prébet Thomas,Rigal-Huguet Françoise,Chabane Kaddour,Magaud Jean-Pierre,Paillet Carole,Pivot Christine,Michallet Mauricette

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference32 articles.

1. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O’Brien;N Engl J Med,2003

2. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med,2006

3. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia;Kantarjian;N Engl J Med,2002

4. Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa;Marin;Lancet,2003

5. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia;Kantarjian;Blood,2003

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape;Leukemia;2021-04-08

2. Role of cancer immunology in chronic myelogenous leukemia;Leukemia Research;2020-01

3. The Role of New TKIs and Combinations with Interferon-α for the Treatment of CML;Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia;2016

4. Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study;The Lancet Haematology;2015-01

5. Second-Line Therapy for Patients With Chronic Myeloid Leukemia Resistant to First-Line Imatinib;Clinical Lymphoma Myeloma and Leukemia;2014-06